Table 4 The number of AS patients in different disease activity assessed in all three phases (n = 126).
Pre-COVID-19-wave phase (A) | COVID-19-wave phase (B) | Post-COVID-19-wave phase (C) | (B)-(A) McNemar p value | (C)-(B) McNemar p value | (C)-(A) McNemar p value | |
|---|---|---|---|---|---|---|
ASDAS-ESR | ||||||
ASDAS ESR < 1.3 | 60 (47.6) | 64 (50.8) | 52 (41.3) | 0.394 | 0.019 | 0.088 |
1.3 ≤ ASDAS ESR < 2.1 | 47 (37.3) | 36 (28.6) | 50 (39.7) | 0.048 | 0.031 | 0.612 |
2.1 ≤ ASDAS ESR ≤ 3.5 | 17 (13.5) | 24 (19.0) | 22 (17.5) | 0.071 | 0.637 | 0.197 |
3.5 < ASDAS ESR | 2 (1.6) | 2 (1.6) | 2 (1.6) | 1.000 | 1.000 | 1.000 |
ASDAS-CRP | ||||||
ASDAS CRP < 1.3 | 68 (54.0) | 64 (50.8) | 63 (50.0) | 0.480 | 0.819 | 0.369 |
1.3 ≤ ASDAS CRP < 2.1 | 39 (31.0) | 40 (31.7) | 41 (32.5) | 0.879 | 0.862 | 0.752 |
2.1 ≤ ASDAS CRP ≤ 3.5 | 18 (14.3) | 19 (15.1) | 19 (15.1) | 0.827 | 1.000 | 0.808 |
3.5 < ASDAS CRP | 1 (0.8) | 3 (2.4) | 3 (2.4) | 0.157 | 1.000 | 0.317 |
BASDAI | ||||||
0 ≤ BASDAI < 3 | 101 (80.2) | 96 (76.2) | 99 (78.6) | 0.225 | 0.439 | 0.480 |
3 ≤ BASDAI < 4 | 13 (10.3) | 11 (8.7) | 11 (8.7) | 0.617 | 1.000 | 0.564 |
4 ≤ BASDAI < 6 | 6 (4.8) | 13 (10.3) | 10 (7.9) | 0.020 | 0.405 | 0.206 |
6 ≤ BASDAI | 6 (4.8) | 6 (4.8) | 6 (4.8) | 1.000 | 1.000 | 1.000 |
